Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000–2013: Vaccine program impact assessment

Abstract Objectives A publicly-funded meningococcal serogroup C conjugate vaccine (MCCV) program was introduced in Ontario, in 2004/2005 for 1-year-old children as well as adolescents (approximately 12 years old). In 2009, quadrivalent meningococcal conjugate vaccine (MCV4) replaced MCCV for grade s...

Full description

Saved in:

Bibliographic Details
Published in:	Vaccine Vol. 33; no. 42; pp. 5678 - 5683
Main Authors:	Wormsbecker, A.E, Wong, K, Jamieson, F.B, Crowcroft, N.S, Deeks, S.L
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier Ltd 13-10-2015 Elsevier Limited
Subjects:	Adolescent Adolescents Adult Age Distribution Aged Aged, 80 and over Allergy and Immunology Child Child, Preschool Conflicts of interest Epidemiology Female Humans Immunization Immunization Programs Incidence Infant Laboratories Male Meningitis Meningococcal infections Meningococcal Infections - epidemiology Meningococcal Infections - prevention & control Meningococcal vaccines Meningococcal Vaccines - therapeutic use Middle Aged Neisseria meningitidis Neisseria meningitidis, Serogroup C Neisseria meningitidis, Serogroup Y Ontario - epidemiology Program Evaluation Public health Risk Factors Serogroup Teenagers Vaccines Vaccines, Conjugate - therapeutic use Young Adult Ontario Canada invasive meningococcal disease IRR incidence rate ratio Epidemiology CFR Meningococcal infections MCV4 case fatality ratio quadrivalent meningococcal vaccine (serogroup A, C, Y and W) deoxyribonucleic acid meningococcal C conjugate vaccine CSF polymerase chain reaction Public health IMD integrated Public Health Information System iPHIS Neisseria meningitidis MCCV PHOL Meningococcal vaccines DNA cerebrospinal fluid Public Health Ontario Laboratories PCR
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!